IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark Edward Bunnage, et :

al.

APPLICATION NO.: To Be Assigned Examiner: To Be Assigned

FILING DATE: Herewith Group Art Unit: To Be Assigned

TITLE: Novel Process For The Preparation of

Pyrazolopyrimidinones

Mail Stop Patent Applications Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEO.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted.

Date: Dec 1, 2003

James T. Jones Attorney for Applicant(s)

Reg. No. 30,561

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 441-4903

INFORMATION DISCLOSURE CITATION							ATTY. DOCKET NO. PC10384B SERIAL NO. To Be Assigned										
(Use several sheets if necessary)							APPLICANT Mark Edward Bunnage, et al.										
Page 1 of 1							FILING DATE Herewith GROUP To Be Assign							ed			
U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL			DOCUMENT NUMBE				;R 		DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	<u> </u>																
						_											
	<u> </u>									-							
	FOREIGN PATENT DOCUMENTS																
DOCUMENT NUMBER									DATE	COUNTRY CLASS		SUBCLASS	TRANSLATION				
	<u> </u>							·						YES	NO		
	wo	0	0	2	4	7_	4	5	4 May 00	Internation	nal	C07D	487/04				
	wo	9	9	6	4	0	0	4	16 Dec 99	Internation	nal	A61K	31/505				
	wo	0	1	2	2	9	1	8	5 April 01	Internation	onal A61K						
	wo	9	4	2	8	9	0	2	22 Dec 94	Internation	nal	A61K	31/505				
	wo	9	8	5	4	3	3	3	3 Dec 98	Internation	nal	C12N	15/57				
	EP	0	8	11	2	8	4	5	17 Dec 97	EPO		C07D	487/04				
	EP	0	4_	6	3	7	5	6	2 Jan 92	EPO		C07D	487/04				
	EP	0	9	1	6	6	7	5	19 May 99	EPO		C07D	487/04				
	DE	2	4	4	4	7	2	0	10 April 75	German		C07C	143-78	x			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																	
		XP00	XP002174403 Rotella, et al., J. Med. Chem. 2000, 43, pgs 1257-1263														
		XP00	XP002174404 Rotella, et al., J. Med. Chem, 2000, 43, pgs 5037-5043														
												<u>-</u> .					
										<u>.</u>							
EXAMINE	R.							DATE C	ONSIDERED								
EXAMINER: next commun	Initial if r	eference cor applicant.	esidered, who	ether or not ci	itation is in co	nformano	ce with MPEP 6	09; Draw line	through citation if n	ot in conformance	and not co	nsidered. I	nclude copy of th	nis form v	vith		

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE